1796 Share Price Performance
Recent 1796 News & Updates
No updates
GeneFerm Biotechnology Co., Ltd. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.19
- Gross Margin
- 20.61%
- Net Profit Margin
- -1.36%
- Debt/Equity Ratio
- 33.1%
GeneFerm Biotechnology Co., Ltd. Competitors
About 1796
- Founded
- 1999
- Employees
- n/a
- CEO
- WebsiteView website
GeneFerm Biotechnology Co., Ltd. develops, manufactures, and sells fermented health care products in Taiwan and internationally. The company offers microbial fermentation products, which includes mushrooms, bacteria, lactic acid bacteria, yeast, and algae; bio fermented ingredients, such as nattomena, natto fermented powder, red yeast rice fermented powder, antrodia cinnamomea mycelia powder, cordyceps, reishi mycelia, phellinus linteus mycelia powder, armillaria mellea mycelia powder, beta-glucan powder, fruits and vegetables fermented enzyme, as well as probiotics and peptide ingredients. It also provides private label supplements; packaging equipment; microbial fermentation toll manufacturing and consulting services. The company was founded in 1999 and is headquartered in Tainan City, Taiwan.
Taiwanese Market Performance
- 7 Days: 0.9%
- 3 Months: 14.1%
- 1 Year: 2.8%
- Year to Date: 0.9%
In the last week, the market has stayed flat, however the Materials sector stood out, gaining 3.3%. In line with that, the market has also been flat over the past year. As for the next few years, earnings are expected to grow by 13% per annum. Market details ›
Companies across the globe are beginning to pay attention to agentic AI. It’s also a term you’re likely to hear a lot during earnings season. In fact, it came up 26 times during...
Continue reading